← back to search

David Kaufman

New York University · US
Area of research
Public Health, Environmental and Occupational Health · Infectious Diseases
Research interest
Research interests include Medicine, Pediatrics, Azithromycin, Necrotizing enterocolitis, Incidence (geometry), and Fluconazole.
h-index
citations
922
works
11
NIH funding
primary concept
email

Recent publications

Identification and Management of Ankyloglossia and Its Effect on Breastfeeding in Infants: Clinical Report
PEDIATRICS 2024cited by 29position: middledoi
Primary Care Framework to Monitor Preterm Infants for Neurodevelopmental Outcomes in Early Childhood
PEDIATRICS 2023cited by 42position: middledoi
GloveCare: a pilot study in preparation for a cluster crossover randomized controlled trial of non-sterile glove-based care in preventing late-onset infection in the NICU
Pilot and Feasibility Studies 2023cited by 6position: middledoi
Use of Probiotics in Preterm Infants
PEDIATRICS 2021cited by 164position: middledoi
Dead space estimates may not be independently associated with 28-day mortality in COVID-19 ARDS
Critical Care 2021cited by 35position: middledoi
Randomised trial of azithromycin to eradicate <i>Ureaplasma</i> in preterm infants
Archives of Disease in Childhood Fetal & Neonatal 2020cited by 89position: middledoi
Changes in the Incidence of Candidiasis in Neonatal Intensive Care Units
PEDIATRICS 2014cited by 161position: middledoi
Effect of Fluconazole Prophylaxis on Candidiasis and Mortality in Premature Infants
JAMA 2014cited by 140position: middledoi
Pharmacokinetics, Microbial Response, and Pulmonary Outcomes of Multidose Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory Colonization
Antimicrobial Agents and Chemotherapy 2014cited by 49position: middledoi
Septicemia mortality reduction in neonates in a heart rate characteristics monitoring trial
Pediatric Research 2013cited by 161position: middledoi
Azithromycin To Prevent Bronchopulmonary Dysplasia in Ureaplasma-Infected Preterm Infants: Pharmacokinetics, Safety, Microbial Response, and Clinical Outcomes with a 20-Milligram-per-Kilogram Single Intravenous Dose
Antimicrobial Agents and Chemotherapy 2013cited by 46position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rose M. Viscardi · University of Maryland, Baltimore3 papers (2013–2020) · 3 papers (2013–2020)Ken B. Waites · University of Alabama at Birmingham3 papers (2013–2020)Natalie D. Eddington · University of Maryland, Baltimore3 papers (2013–2020) · 3 papers (2013–2020)Antonio Arrieta · University of Colorado Denver2 papers (2014–2014)Namasivayam Ambalavanan · Saveetha University2 papers (2014–2020) · 2 papers (2014–2020)Pamela Donohue · Johns Hopkins University2 papers (2014–2020)Daniel K. Benjamin · Duke University2 papers (2014–2014)Robert L. Schelonka · University of Alabama at Birmingham2 papers (2013–2014)Laurence S. Magder · VA Maryland Health Care System2 papers (2014–2020)Kara K. Tsang · London School of Hygiene & Tropical Medicine1 papers (2023–2023)Meredith Mowitz · University of Florida1 papers (2021–2021)Karen M. Puopolo · Eunice Kennedy Shriver National Institute of Child Health and Human Development1 papers (2021–2021)Ahmed A. Othman · Gilead Sciences (Spain)1 papers (2013–2013)Paolo Manzoni · Ospedale Sant'Anna1 papers (2014–2014) · 1 papers (2021–2021)Deborah Tuttle · Thomas Jefferson University1 papers (2020–2020)David A. Randolph · University of Alabama at Birmingham1 papers (2014–2014)